Marinus Pharmaceuticals Shares Owned By Institutions vs. Current Valuation
| MRNS Stock | USD 0.32 0.01 3.03% |
For Marinus Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Marinus Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Marinus Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Marinus Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Marinus Pharmaceuticals over time as well as its relative position and ranking within its peers.
Marinus |
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Marinus Pharmaceuticals. If investors know Marinus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Marinus Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Marinus Pharmaceuticals is measured differently than its book value, which is the value of Marinus that is recorded on the company's balance sheet. Investors also form their own opinion of Marinus Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Marinus Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Marinus Pharmaceuticals' market value can be influenced by many factors that don't directly affect Marinus Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Marinus Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Marinus Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Marinus Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Marinus Pharmaceuticals Current Valuation vs. Shares Owned By Institutions Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Marinus Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Marinus Pharmaceuticals value to that of its competitors to determine the firm's financial worth. Marinus Pharmaceuticals is rated below average in shares owned by institutions category among its peers. It is rated below average in current valuation category among its peers reporting about 382,046 of Current Valuation per Shares Owned By Institutions. Comparative valuation analysis is a catch-all technique that is used if you cannot value Marinus Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Marinus Current Valuation vs. Shares Owned By Institutions
Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
Marinus Pharmaceuticals |
| = | 83.03 % |
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Marinus Pharmaceuticals |
| = | 31.72 M |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Marinus Current Valuation vs Competition
Marinus Pharmaceuticals is rated below average in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is now estimated at about 19.77 Billion. Marinus Pharmaceuticals adds roughly 31.72 Million in current valuation claiming only tiny portion of equities under Health Care industry.
Marinus Pharmaceuticals Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Marinus Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Marinus Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Marinus Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Marinus Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders. The company was incorporated in 2003 and is headquartered in Radnor, Pennsylvania. Marinus Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 113 people.
Marinus Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Marinus Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Marinus Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Marinus Pharmaceuticals' important profitability drivers and their relationship over time.
Use Marinus Pharmaceuticals in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Marinus Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Marinus Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Marinus Pharmaceuticals Pair Trading
Marinus Pharmaceuticals Pair Trading Analysis
The ability to find closely correlated positions to Marinus Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Marinus Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Marinus Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Marinus Pharmaceuticals to buy it.
The correlation of Marinus Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Marinus Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Marinus Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Marinus Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Marinus Pharmaceuticals position
In addition to having Marinus Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Penny Thematic Idea Now
Penny
Solid stocks, funds or ETFs with below average market capitalization and typicl daily price below 2. The Penny theme has 56 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Penny Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Marinus Stock Analysis
When running Marinus Pharmaceuticals' price analysis, check to measure Marinus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Marinus Pharmaceuticals is operating at the current time. Most of Marinus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Marinus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Marinus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Marinus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.